Dual acquisition of (18)F-FMISO and (18)F-FDOPA

Phys Med Biol. 2014 Jul 21;59(14):3925-49. doi: 10.1088/0031-9155/59/14/3925. Epub 2014 Jun 24.

Abstract

Metabolic imaging using positron emission tomography (PET) has found increasing clinical use for the management of infiltrating tumours such as glioma. However, the heterogeneous biological nature of tumours and intrinsic treatment resistance in some regions means that knowledge of multiple biological factors is needed for effective treatment planning. For example, the use of (18)F-FDOPA to identify infiltrative tumour and (18)F-FMISO for localizing hypoxic regions. Performing multiple PET acquisitions is impractical in many clinical settings, but previous studies suggest multiplexed PET imaging could be viable. The fidelity of the two signals is affected by the injection interval, scan timing and injected dose. The contribution of this work is to propose a framework to explicitly trade-off signal fidelity with logistical constraints when designing the imaging protocol. The particular case of estimating (18)F-FMISO from a single frame prior to injection of (18)F-FDOPA is considered. Theoretical experiments using simulations for typical biological scenarios in humans demonstrate that results comparable to a pair of single-tracer acquisitions can be obtained provided protocol timings are carefully selected. These results were validated using a pre-clinical data set that was synthetically multiplexed. The results indicate that the dual acquisition of (18)F-FMISO and (18)F-FDOPA could be feasible in the clinical setting. The proposed framework could also be used to design protocols for other tracers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dihydroxyphenylalanine / analogs & derivatives*
  • Humans
  • Image Processing, Computer-Assisted / methods*
  • Kinetics
  • Misonidazole / analogs & derivatives*
  • Models, Biological
  • Positron-Emission Tomography*
  • Radiation Dosage

Substances

  • fluoromisonidazole
  • fluorodopa F 18
  • Dihydroxyphenylalanine
  • Misonidazole